Epitalon side effects have barely been studied, and that is the honest answer. The few human studies are small, nearly all come from one research network centred in St Petersburg, and none was built to count side effects. When FDA reviewed the peptide in 2026, it found no clinical study of epitalon's safety in people. So "no known side effects" really means "nobody looked carefully", which is a different thing.
A note on names: epitalon and epithalon are two spellings of the same four-amino-acid peptide, and Promise's catalog uses Epithalon. Neither is epithalamin, the cattle pineal-gland extract it was modelled on, which much of the older human data used.
What the human studies say about epitalon side effects
According to FDA's briefing document for its July 2026 advisory committee meeting, three human studies used the synthetic peptide. Two gave it under the tongue to night-shift workers. One gave it by injection beside the eye to people with retinitis pigmentosa, an inherited eye disease.
On tolerability, they say close to nothing:
- Night-shift study. Ivko and colleagues, 2020 gave about 20 women aged 40 to 50 an under-the-tongue spray for 20 days. FDA noted it "did not report safety data."
- Eye study. None of the treated patients reported side effects, as a 2025 review from the Medical University of Warsaw summarises it. That was 10 days of tiny doses, 5 micrograms per eye, which says little about a longer course under the skin.
- A 2007 Russian abstract said the pineal preparations had "no side effects" in older people, with no details on dose, numbers or how side effects were collected.
The Warsaw reviewers put it plainly: "information regarding critical issues about this peptide's safety is missing." The study-by-study story of the epitalon clinical trials has its own page.
Is epitalon safe? Why "no reports" isn't an answer
A side effect nobody measured doesn't show up in a paper.
FDA searched FAERS, its database of voluntary reports about problems with medicines, through December 8, 2025, and found zero reports for epitalon. But as FDA's own footnote says, pharmacies that compound for individual patients under section 503A "generally do not report adverse events to FDA." Zero mostly means nobody filed one.
FDA also listed what's missing: no human pharmacokinetic data (nothing on how epitalon is absorbed, how long it lasts or how it's cleared), no toxicity studies, no reproductive studies, no two-year cancer study. FDA's conclusion: "there are no clinical data to support the safety" of epitalon in humans.
A 2026 review of peptides studied for aging (Mavrych and colleagues, Frontiers in Aging) reached the same place about epitalon and Semax: the absence of serious adverse events in the Russian literature "is encouraging but insufficient for conclusive safety determinations," not least because of publication bias.
What the animal studies do and don't show
The most-cited animal experiment is Anisimov and colleagues, 2003. Fifty-four female mice got epitalon injections five days a month for life; another 54 got salt water. Epitalon didn't change body weight, average lifespan or the overall rate of tumors, and it was linked to less leukemia. The authors read that as a sign of "the safety of its long-term administration in mice."
FDA's reviewers were more cautious. The studies used one fixed dose and female mice only, and total exposure added up to about 22 weeks at most, against the two years of daily dosing a standard cancer study uses. Their verdict: the animal work was "too limited in scope and duration to inform safety considerations" for people.
Does epitalon cause cancer? A theory, not a finding
Epitalon is studied mainly because it switches on telomerase, the enzyme that rebuilds telomeres (the protective caps on chromosome ends that wear down as cells divide). That's also the main worry. Cancer cells lean on telomerase to keep dividing, and inherited variants that lengthen telomeres are strongly associated with cancer risk, as a 2019 Johns Hopkins review sets out.
FDA's briefing said that "from the mechanistic standpoint, epitalon has the potential to be carcinogenic." That is a reason to study the question, not evidence that epitalon causes cancer. No study has shown that it does, and none has ruled it out.
A 2025 cell study from Brunel University London found epitalon lengthened telomeres in normal human cells through telomerase, and also in two breast-cancer cell lines through ALT, a route that doesn't need telomerase (Al-Dulaimi and colleagues, Biogerontology; its figures were corrected in November 2025). What that means in a living body is unknown. It's one reason a personal or family history of cancer is worth raising with a prescriber.
Epitalon risks that come with any injected peptide
Some risks have nothing to do with the molecule. Any injection under the skin can leave redness, swelling or a small lump. An injectable made without sterile technique can carry infection, or endotoxin, bacterial fragments that cause fever and chills.
FDA flagged two more concerns: immunogenicity, meaning the immune system reacting to the peptide itself, which can range from no symptoms to life-threatening reactions and is hard to predict; and aggregation, peptide molecules clumping together, which makes that reaction more likely. FDA's list of compounding substances with safety questions, current as of April 22, 2026, says the agency "lacks sufficient information to know whether the drug would cause harm if administered to humans."
Then there's identity. "Epitalon" is a common name, not an official drug name, and FDA found more than one chemical form sold under it, so a patient "may be dosed with a different bulk drug substance than the physician ordered." A prescription filled by a licensed U.S. compounding pharmacy names the form, strength and lot on its label, under the sterile standards described in how compounded medications are made; a gray-market vial often names none of it.
Epitalon long-term effects and other unknowns
- Long-term effects. No study has followed people on synthetic epitalon for years.
- Pregnancy and breastfeeding. No reproductive safety studies exist. In one rabbit experiment a labelled dose appeared in fetal organs within an hour, though FDA noted the study couldn't prove the signal was epitalon.
- Interactions. Human interaction risks remain unestablished, although a laboratory study found that epitalon increased the growth of ovarian cancer cells and weakened paclitaxel's effect on them. The Warsaw review lists drug and food interactions among the studies still needed.
- Sleep. Epitalon is studied for raising melatonin output, but no study has measured whether that shows up as drowsiness.
- Dose. No standard or maximum dose exists; epitalon dosage covers how prescribers handle that.
People weighing longevity options often set epitalon beside NAD+, whose record is different and also thin: most reported problems are infusion symptoms that stop when the drip does, as NAD injection side effects explains.
How to report a side effect
If something feels wrong, tell the prescriber first, then the pharmacy that filled it, and consider a report to FDA's MedWatch program, which takes reports from patients too. Trouble breathing, swelling of the face or throat, or chest pain is an emergency call, not a message. How to report peptide side effects walks through each step.
Where epitalon stands with FDA
Epitalon has never had an approved product in the United States, and the compounded formulation Promise will offer is not FDA-approved. Epithalon is coming soon to Promise — add me to the list. FDA staff reviewed it for insomnia and proposed not adding it to the 503A bulks list, the list of bulk ingredients that pharmacies compounding for individual patients may draw on. On July 24, 2026, the Pharmacy Compounding Advisory Committee voted 7 to 4 to recommend adding it anyway, as STAT reported. The vote is advisory.
As of September 22, 2026, the day this article was written, FDA had not announced a decision on that recommendation, and its 503A bulks list page was last updated on May 14, 2026. A licensed provider may still prescribe a compounded formulation where they judge it appropriate; that decision is between you and your doctor. What epitalon is studied for is sorted by evidence tier in epitalon benefits.
At Promise, a licensed provider reviews every request, and not everyone qualifies. With a safety record this thin, a decline is a reasonable outcome, and the provider will say why.
